Add us on Google

Multi-Cancer Early Detection Test Guide: Who It Is For and How to Choose

A complete guide to multi-cancer early detection testing, covering who Galleri and LucenceINSIGHT each fit, who they do not, how to choose between them, how to prepare, and how to read results.

Published

August 27, 2026

Last updated

October 20, 2026

Read time

12 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

Summarize with AI

A multi-cancer early detection (MCED) test screens for signals of several cancers at once from a single blood draw. It is an addition to guideline-recommended screening, not a replacement, and it is not a diagnosis. Mito offers two MCED tests with different eligibility: Galleri, which GRAIL recommends for adults with an elevated risk for cancer, such as those age 50 or older, and LucenceINSIGHT, which Lucence positions for adults 40 and older or younger adults with elevated risk. This guide covers who each test fits and who it does not, how to choose between them and among the three LucenceINSIGHT panels, how to prepare, how long results take, and how to read what comes back. Prices live on the product pages and change over time; for the cost breakdown, see the companion article on multi-cancer blood test cost and how to get one.

Who is a multi-cancer early detection test for?

Each test sets its own audience, so read them separately:

• Galleri: GRAIL recommends it for adults with an elevated risk for cancer, such as those age 50 or older ^[1].
• LucenceINSIGHT: Lucence positions it for adults 40 and older, or for people with elevated risk at a younger age, such as a relevant family history, or diet and lifestyle factors that raise concern.

Age matters to both because cancer risk rises with age. If you are in your 40s without other risk factors, LucenceINSIGHT is the one whose published guidance covers you.

The reason the category exists is a real gap. Cancer is the second leading cause of death worldwide per the World Health Organization ^[2], and the majority of US cancer deaths come from cancers with no recommended screening test. Deriving from GLOBOCAN 2024 data and the U.S. Preventive Services Task Force list of screenable cancers ^[3], over half of US cancer deaths fall outside routine screening. Late diagnosis is common: one analysis found 52.8% of cancers are diagnosed at Stage III or IV (Zeng H et al., Lancet 2021), and five-year survival is generally far higher when cancer is caught early, per NIH National Cancer Institute SEER data ^[4]. MCED aims to widen the net beyond the few cancers current programs screen for.

Who is it not for?

MCED testing is not appropriate for everyone, and each test lists its own exclusions.

Galleri is not recommended if you:

• are pregnant,
• are 21 or younger,
• are undergoing active cancer treatment ^[1].

LucenceINSIGHT, subject to your doctor’s judgment, is generally not a fit if you:

• are pregnant,
• have been in cancer remission for less than 3 years (remission <3 years),
• had surgery, an allogeneic bone-marrow transplant, or a blood transfusion less than 2 weeks before the blood draw (<2 weeks before the draw).

Availability also differs by state. Through Mito, Galleri is not currently available in Arizona, Hawaii, New Jersey, New York, or Rhode Island, and LucenceINSIGHT is not currently available in Pennsylvania, New York, or Rhode Island. The product pages show what applies where you live.

Two more limits matter for anyone considering either test. MCED does not assess inherited or germline cancer risk and is not a substitute for genetic counseling. And it does not detect every cancer: cancers that shed little DNA into the bloodstream, such as brain tumors, are hard to detect, and LucenceINSIGHT excludes brain tumors. The clinician review step in the ordering flow is where eligibility is checked, so these situations get caught before a draw.

Galleri or LucenceINSIGHT: which approach fits?

The two tests answer the same broad question in different ways, and neither is better in the abstract.

• Galleri is one fixed test. It looks for a single cancer signal that GRAIL reports is shared by more than 50 types of cancer, many of which have no recommended screening test ^[5]. You do not choose which cancers it covers. It suits people who want the broadest net and who fall within GRAIL’s recommended audience.
• LucenceINSIGHT comes as panels of named cancers. You can take a fixed focused panel, a fixed broad panel, or a panel you and your doctor build around your own risk. It suits people who want to target specific cancers, or who are in their 40s.

Performance figures for the two tests come from different study populations, so they cannot be compared head to head. The side-by-side comparison walks through the rest of the differences.

Core vs Me vs 12: which LucenceINSIGHT panel?

LucenceINSIGHT comes in three panels that differ by breadth and personalization. Breadth maps to how much of US cancer mortality the targeted cancers account for.

• Core screens for signals associated with 6 cancers that together account for more than half of US cancer mortality: thyroid, breast, pancreatic, colorectal, lung, and liver. It is the essential first screen.
• Me is Core plus 1 to 3 more cancers chosen with your doctor from a curated list, for 7 to 9 cancers total depending on how many you add. It is personalized to your family history and personal risk, and its mortality coverage ranges from 53% to 76% depending on which cancers you add.
• 12 is the comprehensive, gender-specific panel covering 12 cancers, roughly 78% of US cancer mortality. The male and female panels differ in which cancers they include.

Wider is not automatically better. A broader panel screens for more cancers, but prediction is imperfect and every signal still has to translate into a next step you would actually take. Me exists because targeted often beats broad for most people: keep the highest-mortality cancers in Core, then add the ones your risk actually points to. If you are unsure where your risk sits, the Cancer Risk Profile quiz is a quick starting point, and the personalized cancer screening plan after 40 walks through building screening around your own risk.

How does each test work?

Galleri reads methylation patterns, chemical tags on cell-free DNA that differ in cancer cells. When it finds a cancer signal, it also predicts the tissue or organ the signal most likely comes from, called the Cancer Signal Origin, so the diagnostic workup can start in the right place ^[6]. GRAIL runs the test in its own CLIA-certified, CAP-accredited laboratory. GRAIL publishes performance data from its studies on its test performance page ^[7]; in the NHS-Galleri trial, around a third of people who had cancer received a positive result, and around half of people with a positive result were diagnosed with cancer ^[8].

LucenceINSIGHT uses next-generation sequencing to detect circulating tumor DNA (ctDNA) and cancer-associated viral DNA. Machine learning then predicts the likely tissue of origin when a signal is found. It is performed by a CLIA/CAP-accredited laboratory (Lucence Health Inc.). In a Lucence validation study across cancer patients at multiple stages (retrospective), overall sensitivity was 80.9% (233 of 288 patients) and specificity was 99.0% (310 of 313 self-declared healthy donors); tumor-localization accuracy was 87.7% overall, with a high-confidence tissue-of-origin prediction possible in 62.4% of cases (Lucence LucenceINSIGHT validation).

Keep two caveats attached to every MCED number: sensitivity varies by cancer type and stage, so a cancer being in a test’s scope does not mean it is equally detectable, and detection is generally easier at later stages than at Stage I.

How do you prepare for the blood draw?

Preparation is light for both tests.

Galleri:

• No fasting and no special preparation are needed.
• The draw happens at a Quest Diagnostics location, and Galleri is placed as its own lab order.
• At checkout you review GRAIL’s Patient Information Sheet, which explains what the test does and its limits.

LucenceINSIGHT:

• No fasting is required.
• Avoid a heavy meal in the 4 hours before your draw.
• The blood is drawn at home, and the sample is collected in 2 x 10 mL Streck tubes.
• If you are on dialysis, have the blood drawn before your dialysis session.

Either order also includes the clinician review that confirms eligibility, so anyone in one of the excluded situations above is identified before the draw.

How long do results take?

Galleri results typically arrive about two weeks after the sample reaches GRAIL’s lab, and in some cases take up to four weeks ^[1]. LucenceINSIGHT takes about 25 working days from sample receipt.

Either way, a result is a snapshot of the moment the blood was drawn. GRAIL says Galleri can be taken annually. That is the manufacturer’s position, not a screening guideline recommendation, and no major U.S. guideline sets an interval for any MCED test, so decide when to test again with your doctor.

Where does MCED fit alongside guideline screening?

MCED supplements guideline-recommended screening and never replaces it. Keep up with mammography, colorectal screening, cervical screening, low-dose CT lung screening if you qualify, and prostate screening as a shared decision with your doctor ^[3]. No major U.S. screening guideline includes MCED testing yet, and whether it reduces cancer deaths has not been shown: the NHS-Galleri trial did not meet its main goal of reducing late-stage diagnoses ^[8], and the U.S. National Cancer Institute’s Vanguard Study is preparing a larger trial to answer that question ^[9].

How do you read the results, and what does a positive mean?

An MCED result is a screening signal, not a diagnosis. That framing drives everything about how to read it:

• A positive result (Galleri calls it Cancer Signal Detected) means a cancer-associated signal was found, usually with a predicted origin. It is not a diagnosis. The next step is a diagnostic workup that your doctor decides on, which may include imaging or tissue sampling directed by the predicted origin. Some people with a positive result turn out not to have cancer.
• A negative result (Galleri calls it No Cancer Signal Detected) does not mean you are cancer-free. It means no signal was detected on this test at this time. Sensitivity varies by cancer and stage, and some cancers are not covered at all, so continue your guideline-recommended screening either way.
• Neither test assesses inherited risk. A result tells you nothing about germline mutations such as BRCA1/2, does not predict future cancer, and is not a substitute for genetic counseling.

The Mito difference

With Mito, the whole path is built around telehealth, so you do not have to source your own doctor’s order: choose a test, a clinician reviews and orders it if appropriate, you get the blood draw, and results return through the telehealth path. For members, an MCED signal does not sit alone. It lands alongside the standard bloodwork and biomarkers Mito already tracks, so the Concierge and your consult can interpret a result in the context of the rest of your health rather than as an isolated report. Membership is $9 per month or $99 per year, and any lab order or draw fee is itemized before you pay.

Ready to choose? For the broadest fixed test, see Galleri. For a panel you can personalize, see LucenceINSIGHT Me, or compare LucenceINSIGHT Core and LucenceINSIGHT 12.

Multi-cancer early detection test questions

Is a multi-cancer early detection test a diagnosis? No. It is a screening test. A positive result needs a diagnostic workup ordered by your doctor, and a negative result does not rule out cancer.

Do I need to fast? No. Neither Galleri nor LucenceINSIGHT requires fasting. For LucenceINSIGHT, avoid a heavy meal in the 4 hours before your draw, and if you are on dialysis, draw before your session.

How many cancers does it screen for? Galleri looks for a signal GRAIL reports is shared by more than 50 cancer types. LucenceINSIGHT Core covers 6 cancers, Me covers 7 to 9 depending on how many you add, and 12 covers 12. More cancers is not automatically better; the right choice depends on your risk.

Am I old enough for Galleri? GRAIL recommends Galleri for adults with an elevated risk for cancer, such as those age 50 or older, and not for anyone 21 or younger. LucenceINSIGHT’s guidance starts at age 40.

Does it check for inherited cancer risk? No. MCED does not assess germline or inherited risk and is not a substitute for genetic counseling.

How often should I test? GRAIL says Galleri can be taken annually, because a result reflects only the moment of the draw. That is the manufacturer’s position, not a guideline recommendation, so set the interval with your doctor.

Can I still skip my regular screenings? No. MCED complements guideline-recommended screening such as mammography and colonoscopy. It does not replace them.

Related guides

• What Is a Multi-Cancer Early Detection (MCED) Test?
• Multi-Cancer Blood Test: What It Costs and How to Get One
• Galleri vs. LucenceINSIGHT: MCED Tests Compared
• Personalized Cancer Screening Plan After 40
• Cancer Antigen 125 (CA-125)

Medical disclaimer

This guide is for informational purposes only. It does not diagnose cancer, recommend a specific test for you, or replace medical care. Multi-cancer early detection is a screening test, not a diagnosis, and it complements rather than replaces guideline-recommended screening. A negative result does not mean you are cancer-free, and a positive result requires diagnostic evaluation ordered by a qualified clinician who considers your symptoms, history, and risk. Galleri and LucenceINSIGHT are prescription-only laboratory-developed tests, and neither has been cleared or approved by the FDA.

References

1. GRAIL: Galleri patient FAQs

2. World Health Organization: Cancer fact sheet

3. U.S. Preventive Services Task Force: Cancer screening recommendations

4. National Cancer Institute SEER: Cancer Stat Facts

5. GRAIL: Types of cancer detected by Galleri

6. GRAIL: Understanding your Galleri results

7. GRAIL: Galleri test performance

8. NHS-Galleri: What the trial found

9. National Cancer Institute: Vanguard Study